Wong IKJ Grulich AE Poynten IM Polizzotto MN van Leeuwen MT Amin J McGregor S Law M Templeton DJ Vajdic CM Jin F, 2021, 'Time trends in cancer incidence in Australian people living with HIV between 19', HIV Medicine, ĭharan NJ Yeh P Bloch M Yeung MM Baker D Guinto J Roth N Ftouni S Ognenovska K Smith D Hoy JF Woolley I Pell C Templeton DJ Fraser N Rose N Hutchinson J Petoumenos K Dawson SJ Polizzotto MN Dawson MA Vincent T Rosario R Lau H Smith D Price S O’Brien J Tan HTL Sinclair B Bascombe F, 2021, 'HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults', Nature Medicine, vol. Murray DD Babiker AG Baker J Barkauskas CE Brown SM Chang CC Davey VJ Gelijns AC Ginde AA Grund B Higgs E Hudson F Kan VL Lane HC Murray TA Paredes R Parmar MKB Pett S Phillips AN Polizzotto MN Reilly C Sandkovsky U Sharma S Teitelbaum M Thompson BT Young BE Neaton JD Lundgren JD, 2021, 'Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)', CLINICAL TRIALS, Lim KJC Di Ciaccio P Hamad N Polizzotto MN Milliken S Cochrane T Goh Z Shaw B Perry E Gilbertson M Kermode W Cheah CY Latimer M Ku M, 2021, 'Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study', Blood, vol. S153 - S163, Ĭarbone A Borok M Damania B Gloghini A Polizzotto MN Jayanthan RK Fajgenbaum DC Bower M, 2021, 'Castleman disease', Nature Reviews Disease Primers, vol. Papot E Kaplan R Vitoria M Polizzotto MN, 2021, 'Optimizing switching strategies to simplify antiretroviral therapy: The future of second-line from a public health perspective', AIDS, vol. Gabrielaite M Bennedbæk M Zucco AG Ekenberg C Murray DD Kan VL Touloumi G Vandekerckhove L Turner D Neaton J Lane HC Safo S Arenas-Pinto A Polizzotto MN Günthard HF Lundgren JD Marvig RL, 2021, 'Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity.', J Infect Dis, vol. He also led capacity development efforts in clinical trials for the NIH in West Africa and Indonesia. National Institutes of Health (NIH), the World Health Organization, Unitaid, and others. During that time in addition to his work in infection-related cancers he led several international randomised trials in HIV, influenza, and COVID-19 infection in collaboration with the U.S. He has published in the most influential journals in his areas of interest, including Blood, Clinical Infectious Diseases, the Journal of Clinical Oncology, Lancet journals, Nature Medicine and the New England Journal of Medicine.įrom 2017 to 2021, Mark was head of the Therapeutic Research Program at the Kirby Institute. Mark's work in clinical trials and therapeutic development has led to new therapy registrations and influenced treatment guidelines in Australia and internationally, while his contributions to translational science have led to paradigmatic shifts in our understanding of the pathogenesis of key viral malignancies and complications of HIV infection. National Institutes of Health, he led international randomised trials of immunotherapies for COVID-19. During the SARS-CoV-2 pandemic, at the invitation of the U.S. Mark's work on viral and HIV-associated cancers has influenced guidelines globally, including co-leading development of an oral immunomodulator for Kaposi sarcoma which led to the first new drug approval for KS in over 20 years. He has a focus on developing new therapies to prevent and treat malignancy, particularly infection-related cancers. Is a clinical triallist whose work sits a the intersection of immunity, infection and cancer. Mark Polizzotto is Professor of Medicine at The Australian National University College of Health and Medicine, where he leads the Clinical Hub in Interventional Research (CHOIR) and is a group leader at the John Curtin School of Medical Research, and Senior Staff Haematologist at The Canberra Region Cancer Centre, Canberra Hospital. People living in low and middle income countries.Gay men and other men who have sex with men.Aboriginal and Torres Strait Islander Peoples.Viral Hepatitis Epidemiology and Prevention Program.
Viral Hepatitis Clinical Research Program.Therapeutic and Vaccine Research Program.